Tividenofusp alfa is named as a drug or biological intervention in 3 clinical trials in our UK and USA trial registers, none of which are currently recruiting. The lead sponsor is Denali Therapeutics Inc.. Registered phases: Phase 2/3 and Phase 1/2. Conditions studied include Mucopolysaccharidosis II.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06075537 | An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 Mucopolysaccharidosis II |
Phase 2/3 | By invitation |
| NCT05371613 | A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) (ClinicalTrials.gov ↗) Mucopolysaccharidosis II |
Phase 2/3 | Active, closed |
| NCT04251026 | A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome (ClinicalTrials.gov ↗) Mucopolysaccharidosis II |
Phase 1/2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Mucopolysaccharidosis II | 3 |
| Lead sponsor | Trials |
|---|---|
| Denali Therapeutics Inc. | 3 |
| Register | Tividenofusp alfa trials |
|---|---|
| Clinical trials in UK | 3 |
| Clinical trials in USA | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tividenofusp alfa works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tividenofusp alfa (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.